Results 51 to 60 of about 142 (121)

Efficacy and Safety of Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis in a China Cohort of a Double‐Blind, Randomised, Phase 3 Trial (ReSTORE China)

Mycoses, Volume 68, Issue 11, November 2025.
ABSTRACT Background The global double‐blind, randomised, Phase 3 ReSTORE trial (NCT03667690) demonstrated noninferiority of rezafungin versus caspofungin for all‐cause mortality at Day 30 and global cure at Day 14 in patients with candidemia and/or invasive candidiasis.
Haihui Huang, Sizhou Feng, Yunsong Yu, Yong Zhang, Yuan Yuan, Laura Cox, Yingyuan Zhang   +6 more
wiley   +1 more source

Rezafungin as Primary Prophylaxis of Pneumocystis jirovecii Pneumonia in a Critically Ill Person Presenting with AIDS with Trimethoprim/Sulfamethoxazole Allergy: A Case Report

Journal of Fungi
Primary prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in people with HIV (PWH) and CD4+ counts
Martina Bottanelli, Alice Mulè, Chiara Molteni, Martina Gerbi, Mauro Pietro Zago, Sara Volpi, Sofia Pettenuzzo, Alessandro Pandolfo, Valentina Morena, Nicole Gemignani, Michele Fogliata, Federico Conti, Alessandra Consonni, Lucia Bradanini, Silvia Pontiggia, Stefania Piconi   +15 more
doaj   +1 more source

Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs

European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.
Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar, Perla Islas‐Jácome, Leonardo D. Herrera‐Zuñiga, Samuel Couve‐Bonnaire, Philippe Jubault, Eduardo González‐Zamora, Jean‐Philippe Bouillon, Alejandro Islas‐Jácome   +7 more
wiley   +1 more source

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae [PDF]

Journal of Antimicrobial Chemotherapy, 2019
AbstractBackgroundRezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species.MethodsWe determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as Saccharomyces cerevisiae. The activity of rezafungin
Tóth, Zoltán, Forgács, Lajos, Locke, Jeffrey B, Kardos, Gábor, Nagy, Fruzsina, Kovács, Renátó, Szekely, Adrien, Borman, Andrew M, Majoros, László   +8 more
openaire   +2 more sources

In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in a Neutropenic Mouse Bloodstream Infection Model

Journal of Fungi
Objectives: Rezafungin is the first new drug approved to treat candidaemia and invasive candidiasis in more than 10 years. However, data are scant on the in vivo efficacy of rezafungin and the other three approved echinocandins against different Candida ...
Dávid Balázsi, Zoltán Tóth, Jeffrey B. Locke, Andrew M. Borman, Lajos Forgács, Noémi Balla, Fruzsina Kovács, Renátó Kovács, Chiaki Amano, Tugba Ilay Baran, László Majoros   +10 more
doaj   +1 more source

Literature review and case report on the use of rezafungin for spondylodiscitis in an outpatient parenteral antimicrobial therapy (OPAT) setting [PDF]

Journal of Bone and Joint Infection
Bone and joint infections secondary to Candida species are associated with high morbidity and mortality, requiring extended courses of antifungal therapy, with parenteral medications being first-line therapy. The reported use of antifungals in outpatient
A. J. Richards, A. J. Richards, A. Asif, M. Ivan, P. J. Lillie, P. J. Lillie, G. Barlow, G. Barlow, C. Walsh   +8 more
doaj   +1 more source

Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi

Advanced Science, Volume 12, Issue 37, October 6, 2025.
The growing burden of drug‐resistant fungal infections, driven by pathogens such as Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, underscores the urgent need for novel antifungal therapies. This review explores antimicrobial peptides as promising agents with membrane‐disruptive activity, immunomodulatory properties, and delivery ...
Cesar Augusto Roque‐Borda, Kaila Petronila Medina‐Alarcón, João Paulo Soler Gonçalves Pereira, Thais Cristina dos Anjos Sevilhano, Brigitte Aguilar‐Morón, Fernando Díaz‐Cárdenas, Lucas Silva da Cruz, Francisco Humberto Xavier‐Júnior, Eduardo Festozo Vicente, João Perdigão, Beatriz G. de la Torre, Fernando Albericio, Fernando Rogério Pavan   +12 more
wiley   +1 more source

Salvage Therapy with Rezafungin for Candida parapsilosis Spondylodiscitis: A Case Report from Expanded Access Program

Microorganisms
Candida spp. spondylodiscitis is a rare condition for which treatment options are often limited. A further obstacle is the duration of therapy, which should be administered for up to twelve months.
Giulio Viceconte, Antonio Riccardo Buonomo, Nunzia Esposito, Letizia Cattaneo, Teresa Somma, Maria Michela Scirocco, Ciro Gabriele Mainolfi, Ivan Gentile   +7 more
doaj   +1 more source

Aspiring Antifungals: Review of Current Antifungal Pipeline Developments

Journal of Fungi, 2020
Invasive fungal infections are associated with significant morbidity and mortality, and their management is restricted to a variety of agents from five established classes of antifungal medication.
Thomas J. Gintjee, Monica A. Donnelley, George R. Thompson   +2 more
doaj   +1 more source

Synthesis and Biological Evaluation of Novel 2‐(Piperidin‐4‐yl)‐1,2,3,4‐tetrahydroisoquinoline and 2‐(Piperidin‐4‐yl)decahydroisoquinoline Antimycotics

Archiv der Pharmazie, Volume 358, Issue 10, October 2025.
A series of 13 hybrid molecules of both lead structures were prepared using reductive amination as key reaction step. The antimycotic potency of the resulting compounds was evaluated against yeast and mold species. Two compounds showed remarkable potency against several yeasts, and even against Candida krusei.
Marie‐Christin Hain, Monika Klimt, Franz Bracher, Ulrike Binder, Jürgen Krauß   +4 more
wiley   +1 more source